Who are Foraseq®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): budesonide/formoterol Turbuhaler 320/9µg, fluticasone and salmeterol, Symbicort Turbohaler without Turbo+, CHF1535, RELVAR/BREO, Budesonide/formoterol Turbuhaler.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/foraseq.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Foraseq® — Competitive Intelligence Brief

Foraseq® (Foraseq®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ICS/LABA combination. Area: Respiratory/Pulmonology.

phase 3 ICS/LABA combination Glucocorticoid receptor; Beta-2 adrenergic receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Foraseq® (Foraseq®) — Eurofarma Laboratorios S.A.. Foraseq is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist for maintenance treatment of asthma and COPD.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Foraseq® TARGET	Foraseq®	Eurofarma Laboratorios S.A.	phase 3	ICS/LABA combination	Glucocorticoid receptor; Beta-2 adrenergic receptor
budesonide/formoterol Turbuhaler 320/9µg	budesonide/formoterol Turbuhaler 320/9µg	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
fluticasone and salmeterol	fluticasone and salmeterol	University of Chicago	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Symbicort Turbohaler without Turbo+	Symbicort Turbohaler without Turbo+	Istituto per la Ricerca e l'Innovazione Biomedica	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
CHF1535	CHF1535	Chiesi Farmaceutici S.p.A.	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
RELVAR/BREO	RELVAR/BREO	GlaxoSmithKline	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor
Budesonide/formoterol Turbuhaler	Budesonide/formoterol Turbuhaler	AstraZeneca	marketed	Inhaled corticosteroid/long-acting beta-2 agonist combination	Glucocorticoid receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ICS/LABA combination class)

Chiesi Farmaceutici S.p.A. · 1 drug in this class
Eurofarma Laboratorios S.A. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Foraseq® — Competitive Intelligence Brief. https://druglandscape.com/ci/foraseq. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab